Terms: = Lymphoma AND RANBP2, NUP358, 5903, ENSG00000153201, P49792, TRP1, TRP2 AND Prognosis
4 results:
1. Abdominal inflammatory myofibroblastic tumour: Clinicopathological and molecular analysis of 20 cases, highlighting potential therapeutic targets.
Vernemmen AIP; Samarska IV; Speel EM; Riedl RG; Goudkade D; de Bruïne AP; Wouda S; van Marion AM; Verlinden IV; van Lijnschoten I; Friederich P; Winnepenninckx VJL; Zur Hausen A; Sciot RME; van den Hout MFCM
Histopathology; 2024 Apr; 84(5):794-809. PubMed ID: 38155480
[TBL] [Abstract] [Full Text] [Related]
2. Epithelioid inflammatory myofibroblastic sarcoma treated with ALK inhibitor: a case report and review of literature.
Liu Q; Kan Y; Zhao Y; He H; Kong L
Int J Clin Exp Pathol; 2015; 8(11):15328-32. PubMed ID: 26823889
[TBL] [Abstract] [Full Text] [Related]
3. ranbp2-ALK fusion combined with monosomy 7 in acute myelomonocytic leukemia.
Lim JH; Jang S; Park CJ; Cho YU; Lee JH; Lee KH; Lee JO; Shin JY; Kim JI; Huh J; Seo EJ
Cancer Genet; 2014; 207(1-2):40-5. PubMed ID: 24613277
[TBL] [Abstract] [Full Text] [Related]
4. Inflammatory myofibroblastic tumor with ranbp2 and ALK gene rearrangement: a report of two cases and literature review.
Li J; Yin WH; Takeuchi K; Guan H; Huang YH; Chan JK
Diagn Pathol; 2013 Sep; 8():147. PubMed ID: 24034896
[TBL] [Abstract] [Full Text] [Related]
